All In Biotech

Drug Trial Radar · NCT06827431

The Research of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression

Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression: A Multicenter, Randomized, Double-blind, Double-Dummy, Placebo-controlled and Sertraline Active-controlled, Parallel-group, Phase III Study

Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 786 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

786

Actual

Start

Feb 21, 2025

Primary completion

Jul 14, 2026

Study completion Aug 20, 2026

Sponsor

Sponsor type
Industry
Collaborators
Shanghai Mental Health Center
First posted
Feb 14, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of Ammoxetine hydrochloride enteric-coated tablets in subjects with depression.

Conditions

  • Major Depressive Disorder (MDD)

Interventions

  • AmmoxetineDrug

    Drug: Ammoxetine Ammoxetine hydrochloride enteric-coated tablets Drug: Placebo placebo to Ammoxetine and Sertraline.

  • AmmoxetineDrug

    Drug: Ammoxetine Ammoxetine hydrochloride enteric-coated tablets Drug: Placebo placebo to Sertraline.

  • PlaceboDrug

    Drug: Placebo placebo to Ammoxetine hydrochlorid and Sertraline.

  • SertralineDrug

    Drug: Sertraline positive control Drug: Placebo placebo to Ammoxetine hydrochlorid.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in Montgomery Asperger Depression Scale (MADRS) score at the end of treatment (week 8)Time frame: From baseline to Week 8

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Peking University Sixth Hospital

    Beijing, Beijing Municipality, China

  • Shanghai Mental Health Center

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.